Summit Partners Public Asset Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
Other funds holding SRPT
ACA
FCM
Summit Partners Public Asset Management's SRPT Position: Q1 2025 in Review
Summit Partners Public Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 379,150 shares — an estimated $46.1M sold.
Summit Partners Public Asset Management first reported a position in SRPT in Q4 2017 and held it in 12 quarters. The position peaked at $46.1M in Q4 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.
- Summit Partners Public Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
- Summit Partners Public Asset Management sold 379,150 Sarepta Therapeutics shares in Q1 2025, an estimated $46.1M.
- Summit Partners Public Asset Management first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 12 quarters.
- Summit Partners Public Asset Management's Sarepta Therapeutics position peaked at $46.1M in Q4 2024.
- 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.
Based on Summit Partners Public Asset Management's 13F filing for Q1 2025, filed 15 May 2025.